Type your tag names separated by a space and hit enter

meningococcal group B vaccine


me-nin-go-kok-al groop B vax-seen

Trade Name(s)

  • Bexsero
  • Trumenba

Ther. Class.
vaccines/immunizing agents

Pharm. Class.


  • Bexsero– Provides active immunization against invasive meningococcal disease caused by 3 strains of Neisseria meningitidis serogroup B (strains prevalent in the US).
  • Tremenba– Provides active immunization against invasive meningococcal disease caused by 4 strains of Neisseria meningitidis serogroup B (strains prevalent in the US).


Induces production of antibodies to several strains of serogroup B Neisseria meningitidis.

Therapeutic Effect(s):

Prevention of invasive meningococcal disease.


Absorption: Well absorbed following IM administration.

Distribution: Unknown.

Metabolism and Excretion: Unknown.

Half-life: Unknown.

TIME/ACTION PROFILE (antibody response)

IMwithin 2 mounknownunknown


Contraindicated in:

  • Severe allergic reaction to a previous dose
  • Latex allergy (Bexsero tip caps contain latex).

Use Cautiously in:

  • Geri: Safe and effective use in patients >65 yr has not been established;
  • Lactation:Use cautiously if breastfeeding;
  • OB: Use during pregnancy only if clearly needed;
  • Pedi: Safe and effective use in children <10 yr not established (>90% risk of fever in infants <12 mo).

Adverse Reactions/Side Effects

CNS: fatigue, headache

GI: nausea, diarrhea, vomiting

Local: injection site reactions

MS: arthralgia, mylagia

Misc: allergic reactions including anaphylaxis, chills, fever, syncope

* CAPITALS indicate life-threatening.
Underline indicate most frequent.



Concurrent use of immunosuppressivesmay ↓ the desired immune response.



IM: (Adults and Children 10–25 yr): Two 0.5 mL doses one mo apart.


IM: (Adults and Children 10–25 yr): 0.5 mL followed by a second dose 2 mo later and a third dose 4 mo after the second dose.


Suspension for IM injection (Bexsero tip caps contain latex): 0.5 mL in pre-filled syringes


  • Monitor for signs and symptoms of allergic reaction (dyspnea, rash, hives, swelling of face, lips, or throat). Keep epinephrine, an antihistamine, and resuscitation equipment close by in the event of an anaphylactic reaction.
  • Assess for latex allergy. Bexsero tip cap contains latex.
  • Assess for syncope. Make patient is sitting or lying down during and immediately following injections.

Potential Diagnoses


  • IM: Shake syringe vigorously for a homogenous white suspension; do not use if solution has separated, discolored, or contains particulate matter. Administer 0.5 mL IM into deltoid muscle of upper arm. Do not mix with other vaccines in same syringe.

Patient/Family Teaching

  • Explain purpose of vaccine to patient/parent. Emphasize need for 2 doses of immunization series for Bexsero or 3 doses for Tremenba.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

Prevention of invasive meningococcal disease including meningitis.

meningococcal group B vaccine is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Emergency Central is a collection of disease, drug, and test information including 5-Minute Emergency Medicine Consult, Davis’s Drug, McGraw-Hill Medical’s Diagnosaurus®, Pocket Guide to Diagnostic Tests, and MEDLINE Journals created for emergency medicine professionals. Learn more.


Quiring, Courtney, et al. "Meningococcal Group B Vaccine." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Emergency Central, emergency.unboundmedicine.com/emergency/view/Davis-Drug-Guide/110176/all/meningococcal_group_B_vaccine.
Quiring C, Sanoski CA, Vallerand AH. Meningococcal group B vaccine. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://emergency.unboundmedicine.com/emergency/view/Davis-Drug-Guide/110176/all/meningococcal_group_B_vaccine. Accessed April 19, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Meningococcal group B vaccine. In Davis's Drug Guide. Available from https://emergency.unboundmedicine.com/emergency/view/Davis-Drug-Guide/110176/all/meningococcal_group_B_vaccine
Quiring C, Sanoski CA, Vallerand AH. Meningococcal Group B Vaccine [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 April 19]. Available from: https://emergency.unboundmedicine.com/emergency/view/Davis-Drug-Guide/110176/all/meningococcal_group_B_vaccine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - meningococcal group B vaccine ID - 110176 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://emergency.unboundmedicine.com/emergency/view/Davis-Drug-Guide/110176/all/meningococcal_group_B_vaccine PB - F.A. Davis Company ET - 16 DB - Emergency Central DP - Unbound Medicine ER -